<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-r-chp-pgi-dlbcl-zhao">
    <meta name="study:title" content="PB3309 - Pola-R-CHP regimen demonstrates high efficacy and manageable safety in newly diagnosed primary gastrointestinal diffuse large B-cell lymphoma">
    <meta name="study:fileName" content="Abstracts/POLARCHP-PGI-DLBCL-ZHAO.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Polatuzumab Vedotin,Rituximab,ADC,Monoclonal Antibody,Chemotherapy,CIT,Pola-R-CHP">

    <title>PB3309: Pola-R-CHP in 1L Primary Gastrointestinal DLBCL (Zhao) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> 
</head>
<body class="abstract-page-body"> 
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3309 - Pola-R-CHP in 1L Primary Gastrointestinal DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=16)</h4>
                    <p>Newly diagnosed Primary Gastrointestinal DLBCL (PGI-DLBCL). Aim: Evaluate Pola-R-CHP efficacy & safety.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention</h4>
                    <p>Pola-R-CHP regimen (Polatuzumab, Rituximab, Cyclophosphamide, Liposomal Doxorubicin, Prednisone).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (EOT, N=16)</h4>
                    <p>ORR: <span class="highlight-value">68.8%</span>CRR: <span class="highlight-value">68.8%</span></p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Good tolerability. Gr 3/4 Neutropenia (31.3%). High efficacy, warrants further trials.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3309: Pola-R-CHP regimen demonstrates high efficacy and manageable safety in newly diagnosed primary gastrointestinal diffuse large B-cell lymphoma</h1>
            <p class="abstract-sub-header">Real-World Data from Multi-Centers in China</p>
            <p class="abstract-meta-info mt-2">Xia Zhao, Zhihe Liu | EHA Library PB3309 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Primary gastrointestinal diffuse large B cell lymphoma (PGI-DLBCL) is common (approx. 40% of extra-nodal lymphomas).</li>
                        <li>Survival for PGI-DLBCL patients remains poor despite 1L R-CHOP.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the novel Pola-R-CHP regimen (polatuzumab vedotin, rituximab, cyclophosphamide, liposomal doxorubicin, and prednisone) in treatment-naïve PGI-DLBCL patients.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Retrospective analysis of newly diagnosed PGI-DLBCL patients.</li>
                        <li>Setting: Single hospital in China (patients treated between Jan 2023 - Dec 2024).</li>
                        <li>All patients underwent NGS for TP53 mutations (exons 5-8).</li>
                        <li>Response assessment by PET-CT.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Pola-R-CHP Treatment Regimen</h3>
                        <div class="schema-step">
                            <strong>Patient Enrollment (N=16)</strong>
                            <span>Newly Diagnosed PGI-DLBCL</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-step">
                            <strong>Treatment: Pola-R-CHP (q21d)</strong>
                            <span>Polatuzumab vedotin: 1.8 mg/kg (D1)</span>
                            <span>Rituximab: 375 mg/m² (D1)</span>
                            <span>Cyclophosphamide: 750 mg/m² (D1)</span>
                            <span>Liposomal Doxorubicin: 30 mg/m² (D1)</span>
                            <span>Prednisone: 100 mg PO QD (D1-5, first 6 cycles)</span>
                            <span class="text-xs mt-1">(All pts completed ≥3 cycles)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Response after 3 Cycles</span>
                           <span>Response at End of Treatment (EOT)</span>
                           <span>Adverse Events</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=16)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>66 (54-79)</td></tr>
                                <tr><td>Male : Female Ratio</td><td>5:3</td></tr>
                                <tr><td>Ann Arbor Stage III/IV, n (%)</td><td>5 (31.2%)</td></tr>
                                <tr><td>IPI Score ≥3, n (%)</td><td>7 (43.8%)</td></tr>
                                <tr><td>Non-GCB (Hans), n (%)</td><td>12 (75.0%)</td></tr>
                                <tr><td>Median Ki-67, % (range)</td><td>80% (70-95%)</td></tr>
                                <tr><td>P53 protein expression >50%, n (%)</td><td>12 (75.0%)</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (N=16)</h2>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">📊</div>
                            <div class="infographic-value">100%</div>
                            <div class="infographic-label">ORR after 3 Cycles</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">🎯</div>
                            <div class="infographic-value">37.5%</div>
                            <div class="infographic-label">CRR after 3 Cycles</div>
                        </div>
                    </div>
                     <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">📊</div>
                            <div class="infographic-value">68.8%</div>
                            <div class="infographic-label">ORR at EOT</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">🎯</div>
                            <div class="infographic-value">68.8%</div>
                            <div class="infographic-label">CRR at EOT</div>
                        </div>
                    </div>
                    
                    <div class="chart-container mb-6">
                        <svg id="polaRCHPeotResponseChart" width="350" height="300"></svg>
                        <div id="polaRCHPeotResponseLegend" class="legend"></div>
                    </div>
                </div>
                
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=16)</h2>
                    <p class="text-sm">Adverse events were generally mild.</p>
                    <p class="text-sm mt-2"><strong>Most Common Adverse Events:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-1">
                        <li>Hematologic toxicities were most common.</li>
                        <li>Grade 3/4 Neutropenia after 3 cycles: 5 pts (31.3%)</li>
                        <li>(Abstract mentions G1/2 CRS and tumor flare as common for glofitamab regimens in general context, but not specifically for Pola-R-CHP in this cohort)</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The Pola-R-CHP regimen demonstrated <strong class="highlight">high efficacy</strong> and <strong class="highlight">good tolerability</strong> in patients with newly diagnosed PGI-DLBCL.</li>
                <li>Its favorable safety profile and durable responses suggest potential superiority over R-CHOP, warranting further validation in larger randomized trials.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>
                1L, First-line; ADC, Antibody-Drug Conjugate; AE, Adverse Event; C, Cyclophosphamide; CHP, Cyclophosphamide, Doxorubicin, Prednisone; CI, Confidence Interval; CIT, Chemoimmunotherapy; CR, Complete Response; CRR, Complete Response Rate; CRS, Cytokine Release Syndrome; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; EOT, End of Treatment; GCB, Germinal Center B-cell like; Glo, Glofitamab; H, Doxorubicin (Hydroxydaunorubicin); IPI, International Prognostic Index; IV, Intravenous; LBCL, Large B-Cell Lymphoma; mg/kg, milligrams per kilogram; mg/m², milligrams per square meter; NHL, Non-Hodgkin Lymphoma; NGS, Next-Generation Sequencing; ORR, Overall Response Rate; OS, Overall Survival; P, Prednisone; PD, Progressive Disease; PET-CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; PGI-DLBCL, Primary Gastrointestinal Diffuse Large B-Cell Lymphoma; Pola, Polatuzumab Vedotin; PO, Per Os (by mouth); PR, Partial Remission; Pts, Patients; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R/R, Relapsed/Refractory; SD, Stable Disease.
            </p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-4 h-4 mr-1.5">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Zhao X, Liu Z. Pola-R-CHP regimen demonstrates high efficacy and manageable safety in newly diagnosed primary gastrointestinal diffuse large B-cell lymphoma. Abstract #PB3309 presented at European Haematology Association (EHA) June 12–15, 2025.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA Library PB3309 | Presentation Date: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script> 
    <script>
        function drawStackedBarChart(containerId, legendContainerId, chartData, chartTitle) {
            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = chartWrapper.getBoundingClientRect().width * 0.8; 
            }
            containerWidth = Math.max(containerWidth, 250);

            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 40, right: 20, bottom: 50, left: 60 }; 
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"]; 
            const stack = d3.stack().keys(chartData.keys);
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.7); 

            const yScale = d3.scaleLinear()
                .domain([0, 100]) 
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([])) 
                .select(".domain").remove(); 

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");
            
            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                  .attr("class", "serie")
                .selectAll("rect")
                .data(d => d) 
                .enter().append("rect")
                    .attr("x", d => xScale(categories[0]))
                    .attr("y", d => yScale(d[1]))
                    .attr("height", d => yScale(d[0]) - yScale(d[1]))
                    .attr("width", xScale.bandwidth())
                    .attr("fill", (d, i, nodes) => { 
                        const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                        return color(seriesKey);
                    })
                    .attr("rx", 3).attr("ry", 3);
            
            stackedData.forEach((series) => {
                series.forEach((d) => { 
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 4) { 
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4) 
                            .attr("text-anchor", "middle")
                            .style("fill", (series.key === "CR" || series.key === "Other (SD/PD/NR)") ? "white" : "var(--sobi-dark-blue)") 
                            .style("font-size", "10px")
                            .text(`${percentage.toFixed(1)}%`);
                    }
                });
            });

            if (chartData.orr) {
                 g.append("text")
                    .attr("class", "chart-label")
                    .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                    .attr("y", yScale(chartData.orr) - 12) 
                    .attr("text-anchor", "middle")
                    .style("font-weight", "600")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${chartData.orr.toFixed(1)}%`);
            }
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.map(key => {
                if (chartData.values[key] > 0) { 
                    return {
                        label: `${key} (${chartData.values[key].toFixed(1)}%)`,
                        color: color(key)
                    };
                }
                return null;
            }).filter(item => item !== null); 

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        // Data for Pola-R-CHP EOT Response Chart (N=16)
        // EOT: ORR 68.8%, CRR 68.8% => PRR = 0%
        // Other (SD/PD/NR) = 100 - 68.8 = 31.2%
        const polaRchpEOTResponseData = {
            keys: ["CR", "Other (SD/PD/NR)"], // PR is 0%
            values: { 
                CR: 68.8, 
                PR: 0.0,
                "Other (SD/PD/NR)": 31.2 
            }, 
            colors: ["var(--sobi-teal)", "var(--sobi-medium-gray-text)"], // Colors for CR and Other
            orr: 68.8 
        };
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawPolaRCHPChart = debounce(() => drawStackedBarChart("#polaRCHPeotResponseChart", "#polaRCHPeotResponseLegend", polaRchpEOTResponseData, "Response at End of Treatment (N=16)"), 250);
        
        window.addEventListener('resize', () => {
            debouncedDrawPolaRCHPChart();
        });
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawPolaRCHPChart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(() => {
                debouncedDrawPolaRCHPChart();
             }, 0); 
        }
    </script>
</body>
</html>
